HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

RVTY

Revvity, Inc.

Healthcare — Diagnostics & Research

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Buy 2.3 / 5 15 analysts
$149.12
$-3.77 (-2.47%)
Target: $113.73 (-23.7%)

Price History

52-Week Range
Sign in to add RVTY to a watchlist or set price alerts.

Fundamentals

Market Cap$12.59B
P/E Ratio (TTM)54.25
Forward P/E19.36
EPS (TTM)$2.08
Dividend Yield0.25%
Profit Margin8.26%
Revenue Growth7.00%
ROE3.23%
Debt/Equity46.64
Recommendation Buy 2.3
Analyst Target$113.73
Analysts15
Next Earnings Aug 4, 2026 BMO
Indexes -

Technical Indicators

RSI (14)70.2
Beta1.11
SMA 20-
SMA 40-
52-Week High$118.30
52-Week Low$81.22
50-Day Avg$98.10
200-Day Avg$96.47
Avg Volume$1.44M
Volume$1.20M

Performance Analysis

BEARISH

RVTY is flashing more cautionary signals — investors should monitor closely.

- Trading near its 52-week high ($118.30), which may indicate limited upside.
- RSI at 70.2 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
- P/E of 54.2 is elevated — the market expects high growth or it may be overvalued.
~ Modest revenue growth of 7.0% year-over-year.
+ Wall Street consensus is "Buy" from 15 analysts.
- Average analyst target of $113.73 implies 23.7% downside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:29 UTC

Back to Screener Export Report